Extended Data Fig. 6: 3P10 blocks tumor-induced muscle wasting and preserves muscle function.

a, Gastrocnemius (top), tibialis anterior (middle) and soleus (bottom) muscle mass measured on day 22 from non-tumor bearing (NTB) and HT1080 tumor-bearing mice treated with 3 mg/kg IgG1 or 3P10 (See Extended Data Fig. 4c). n = 10 per group. b, Serum 3-methyl-histidine, a biomarker for muscle breakdown, 24 hours after antibody treatment of HT1080 tumor-bearing mice treated with 3 mg/kg IgG1 or 3P10, and non-tumor bearing controls. n = 6 per group. c, Differentially expressed genes identified by RNA sequencing of gastrocnemius muscle of IgG1 treated HT1080 tumor-bearing compared to non-tumor bearing mice, that are reversed by 3P10. n = 5 per group. Muscle was collected on day 22 (See Extended Data Fig. 4c). Muscle specific genes identified by Ingenuity Pathway Analysis are listed, including markers for muscle atrophy (bold). See Extended Table 3 for full list. d, Fbxo32 (top) and TRIM63 (bottom) muscle atrophy gene expression measured by RT-qPCR of HT1080 tumor bearing mice treated with 3 mg/kg IgG1 or 3P10 antibody. n = 6 per group. Gene expression was assessed on day 22 (See Extended Data Fig. 4c). e, Muscle function measured by grip strength measured on day 22 from non-tumor bearing (NTB) and HT1080 tumor-bearing mice treated with 3 mg/kg IgG1 or 3P10 (See Extended Data Fig. 4c). Bar graph represents n = 150 measurements collected from 6 mice, each of which 25 repeat measures of grip strength were counted. In a,b and d,e, data represent mean ± s.e.m. Numbers above denote p-values analyzed by ANOVA.